Association between gene polymorphism and adverse effects in cancer patients receiving docetaxel treatment: a meta-analysis

2022 ◽  
Author(s):  
Mingrui Yan ◽  
Xiaoyu Fan ◽  
Hongyanhua Si ◽  
Xiaoyu Wang ◽  
Zhe Wang ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Gene Polymorphism ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Docetaxel Treatment

Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis

Breast Cancer ◽  
2017 ◽  
Vol 25 (1) ◽  
pp. 17-27 ◽  
Author(s):  
Loay Kassem ◽  
Kyrillus S. Shohdy ◽  
Shaimaa Lasheen ◽  
Omar Abdel-Rahman ◽  
Thomas Bachelot
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Adverse Effects ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Cyclin Dependent Kinase ◽  
Breast Cancer Patients

scholarly journals Oral adverse effects of CDK4/6 inhibitors among breast cancer patients: a systematic review and meta-analysis

2021 ◽  
Vol 0 (0) ◽  
pp. 0-0
Author(s):  
Quanyi Long ◽  
Xiaomin Li ◽  
Gonghua Wu ◽  
Jia Zhang ◽  
Hongjiang Li
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Adverse Effects ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Breast Cancer Patients

Incidence and clinical pattern of immune related adverse effects (irAE) due to immune checkpoint inhibitors (ICI).

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e14151-e14151 ◽  
Author(s):  
Bicky Thapa ◽  
Joanna Roopkumar ◽  
Ann S Kim ◽  
Lorenzo Gervaso ◽  
Pradnya Dinkar Patil ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Cancer Patients ◽  
Checkpoint Inhibitors ◽  
Meta Analysis ◽  
Descriptive Analysis ◽  
Cleveland Clinic ◽  
Retrospective Chart Review ◽  
Pooled Analysis ◽  
Advanced Malignancies

e14151 Background: ICIs have revolutionized outcomes in many advanced malignancies, however their use is associated with irAEs. Methods: An IRB-approved, retrospective chart review was done using the Cleveland Clinic pharmacy database. Patients were included who received six FDA approved (nivolumab, ipilimumab, pembrolizumab, atezolizumab, avelumab, or durvalumab) ICIs from July 2015 to December 2017. irAEs were identified from review of electronic medical records. Descriptive analysis was done to evaluate the incidence, pattern, and severity of irAEs. Results: A total of 1091 patients received ICI therapy, 651 (59.7%) were male, 958 (87.4%) white, 95 (8.7%) black. Lung cancer (540, 49.5%) comprised the majority of the cohort, followed by melanoma (152, 13.9%), and renal cell carcinoma (121, 11.1%). About 996 (91.3%) received treatment with only one ICI, 85 (7.8%) with 2 ICIs, and only 10 patients received 3 ICIs. A total of 487 (44.63%) patients encountered irAEs, 128 (11.73%) resulting in treatment cessation. Fatigue (152, 13.9%) was the most common, followed by dermatologic irAEs (131, 12%). Endocrine irAEs occurred in 108 (9.89%), GI toxicities, namely diarrhea and colitis, were seen in 92 (8.4%) and hepatotoxicity in 54 (4.94%). Other irAEs including rheumatologic, pneumonitis, renal, and neurological adverse effects were documented in 6.5%, 5.1%, 2.56%, and 2.01% respectively. Rare irAEs such as ocular toxicity, cardiac toxicity, and vasculitis were seen in 0.8%, 0.73%, and 0.54%, respectively. Compared with a pooled analysis from clinical trials (De Velasco G et al. Comprehensive Meta-analysis of Key irAEs from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients) dermatologic irAEs and fatigue were less frequent; diarrhea/colitis, pneumonitis and rheumatologic irAEs were more frequent. Conclusions: irAEs on ICI therapy are very common. Awareness of the relative frequencies of various irAEs, particularly severe and rare irAEs, in a real-world setting can help improve quality of care for cancer patients receiving ICI. [Table: see text]

Investigation of Thymidylate synthase gene polymorphism in colon cancer patients

2012 ◽  
Vol 50 (05) ◽  
Author(s):  
A Schöller ◽  
A Kalmár ◽  
VÁ Patai ◽  
Z Nagy ◽  
B Barták ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Gene Polymorphism ◽  
Cancer Patients ◽  
Thymidylate Synthase

Thrombosis in Cancer Patients Treated with Hematopoietic Growth Factors - A Meta-Analysis

1996 ◽  
Vol 75 (02) ◽  
pp. 368-371 ◽  
Author(s):  
T Barbul ◽  
G Finazzi ◽  
A Grassi ◽  
R Marchioli
Keyword(s):  
Cancer Patients ◽  
Case Reports ◽  
Meta Analysis ◽  
Case Series ◽  
Hematopoietic Growth Factors ◽  
Patients With Cancer ◽  
Cytotoxic Treatment ◽  
Pertinent Data ◽  
Thrombotic Complications ◽  
Vascular Occlusions

SummaryHematopoietic colony-stimulating factors (CSFs) are largely used in patients with cancer undergoing cytotoxic treatment to accelerate neutrophil recovery and decrease the incidence of febrile neutropenia. Clinical practice guidelines for their use have been recently established (1), taking into account clinical benefit, but also cost and toxicity. Vascular occlusions have been recently reported among the severe reactions associated with the use of CSFs, in anedoctal case reports (2, 3), consecutive case series (4) and randomized clinical trial (5, 6). However, the role of CSFs in the pathogenesis of thrombotic complications is difficult to ascertain, because pertinent data are scanty and widely distributed over a number of heterogenous investigations. We report here a systematic review of relevant articles, with the aims to estimate the prevalence of thrombosis associated with the use of CSFs and to assess if this rate is significantly higher than that observed in cancer patients not receiving CSFs.

Sign in / Sign up

Export Citation Format

Share Document